SCHEMBL2064868

SCHEMBL2064868

CCN(CC)Cc1sc(-c2nc(-c3ccc(C(=O)NCCO)cc3)no2)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.49
HDAC4 P56524 7/20 0.48
HDAC6 Q9UBN7 5/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC1 Q13547 2/20 0.48
HDAC3 O15379 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
S1PR1 P21453 9/20 0.45
S1PR3 Q99500 6/20 0.45
RARA P10276 1/20 0.43
RARB P10826 1/20 0.43
RARG P13631 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
S1PR5 Q9H228 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2065005 0.91 HDAC4 (0.52) MCHR1HDAC4HDAC6HDAC2HDAC8
SCHEMBL2065252 0.89 MCHR1 (0.47) MCHR1HDAC4HDAC6HDAC2HDAC8
SCHEMBL2064521 0.86 MCHR1 (0.45) MCHR1HDAC4HDAC6HDAC2HDAC8
SCHEMBL2064223 0.85 RARA (0.59) S1PR1S1PR3RARARARBRARG
SCHEMBL2065383 0.84 S1PR1 (0.46) S1PR1S1PR3RARARARBRARG
SCHEMBL2064418 0.84 HDAC4 (0.43) HDAC4HDAC6S1PR1S1PR3RARA
SCHEMBL2064483 0.83 S1PR1 (0.40) S1PR1S1PR3RARARARBRARG
SCHEMBL2064361 0.83 S1PR1 (0.46) S1PR1S1PR3ALDH1A1S1PR5
SCHEMBL2064613 0.83 S1PR1 (0.52) S1PR1S1PR3S1PR5
SCHEMBL2064853 0.83 RARA (0.46) S1PR1S1PR3RARARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222667-B1 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2013-02-20 EP disclosed
US-8148410-B2 Thiophene derivatives as agonists of S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2012-04-03 US disclosed
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2010-10-14 US disclosed
EP-2222667-A2 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 Actelion Pharmaceuticals Ltd. (CH) 2010-09-01 EP disclosed
WO-2009074950-A2 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 S1PR1, S1PR3, S1PR5 MCHR1 335/4885HDAC4 2657/4885HDAC6 3848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.